Novartis在2025年11月推出美国直诊平台, 提供55%现金折扣的 Cosentyx。 Novartis to launch U.S. direct-to-patient platform in Nov. 2025, offering Cosentyx at 55% cash discount.

2025年11月,诺华将在美国推出直接向患者提供平台,为现金支付的患者提供其最销的药物Cosentyx,并将价格与保险公司和PBM折扣相匹配. In November 2025, Novartis will launch a direct-to-patient platform in the U.S., offering its top-selling drug Cosentyx at a 55% discount for cash-paying patients, aligning prices with insurer and PBM discounts. 这一举动是PhRMA领导的更广泛行业努力的一部分,旨在通过计划中的500亿美元的美国投资和2026年1月推出的新患者定价门户网站来降低成本和改善访问. This move, part of a broader industry effort led by PhRMA, aims to cut costs and improve access through $500 billion in planned U.S. investments and a new patient pricing portal launching in January 2026. 该倡议支持扩大财政援助,并反映了行业走向直接销售的日益增长的势头,诺华公司还探索了直接对雇主的模式。 The initiative supports expanded financial aid and reflects growing industry momentum toward direct sales, with Novartis also exploring direct-to-employer models.